The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
Open accessAbstract
Inhibitors selective for prostaglandin G/H synthase-2 (PGHS-2) (known colloquially as COX-2) were designed to minimize gastrointestinal complications of traditional NSAIDs--adverse effects attributed to suppression of COX-1-derived PGE2 and prostacyclin (PGI2). Evidence from 2 randomized controlled-outcome trials (RCTs) of 2 structurally distinct selective inhibitors of COX-2 supports this hypothesis. However, 5 RCTs of 3 structurally distinct inhibitors also indicate that such compounds elevate the risk of myocardial infarction and stroke. The clinical information is biologically plausible, as it is compatible with evidence that inhibition of COX-2-derived PGI2 removes a protective constraint on thrombogenesis, hypertension, and atherogenesis in vivo. However, the concept of simply tipping a "balance" between COX-2-derived PGI2 and COX-1-derived platelet thromboxane is misplaced. Among the questions that remain to be addressed are the following: (a) whether this hazard extends to all or some of the traditional NSAIDs; (b) whether adjuvant therapies, such as low-dose aspirin, will mitigate the hazard and if so, at what cost; (c) whether COX-2 inhibitors result in cardiovascular risk transformation during chronic dosing; and (d) how we might identify individuals most likely to benefit or suffer from such drugs in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A., & Vane, J. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7563 · Cited by 1,519
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
Picot, D., Loll, P. J., & Garavito, R. M. (1994) · Nature · doi:10.1038/367243a0 · Cited by 1,265
Low-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Trials to assess equivalence: the importance of rigorous methods: Fig 1
Jones, B., Jarvis, P., Lewis, J. A., & Ebbutt, A. F. (1996) · BMJ · doi:10.1136/bmj.313.7048.36 · Cited by 1,032
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Coxibs and Cardiovascular Disease
FitzGerald, G. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048288 · Cited by 899
Moncada, S., Higgs, E. A., & Vane, J. R. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91655-5 · Cited by 882
Topper, J. N., Cai, J., Falb, D., & Gimbrone, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10417 · Cited by 843
cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase.
O'Banion, M. K., Winn, V. D., & Young, D. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4888 · Cited by 821
Simon, L. S., Weaver, A. L., Graham, D. Y., Kivitz, A. J., Lipsky, P. E., Hubbard, R. C., Isakson, P. C., Verburg, K. M., Yu, S. S., Zhao, W. W., et al. (1999) · JAMA · doi:10.1001/jama.282.20.1921 · Cited by 798
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., & FitzGerald, G. A. (2002) · Science · doi:10.1126/science.1068711 · Cited by 789
Self-citationAltered pain perception and inflammatory response in mice lacking prostacyclin receptor
Murata, T., Ushikubi, F., Matsuoka, T., Hirata, M., Yamasaki, A., Sugimoto, Y., Ichikawa, A., Aze, Y., Tanaka, T., Yoshida, N., et al. (1997) · Nature · doi:10.1038/41780 · Cited by 773
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., & Prescott, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52976-8 · Cited by 708
Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16893-1 · Cited by 701
Adverse Upper Gastrointestinal Effects of Rofecoxib Compared With NSAIDs
Langman, M. J. (1999) · JAMA · doi:10.1001/jama.282.20.1929 · Cited by 686
Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
Luong, C., Miller, A., Barnett, J., Chow, J., Ramesha, C., & Browner, M. F. (1996) · Nature Structural Biology · doi:10.1038/nsb1196-927 · Cited by 618
Catella-Lawson, F., McAdam, B., Morrison, B. W., Kapoor, S., Kujubu, D., Antes, L., Lasseter, K. C., Quan, H., Gertz, B. J., & Fitzgerald, G. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38195-9 · Cited by 597
Genetic and pharmacological analysis of prostanoid receptor function
Narumiya, S., & FitzGerald, G. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13455 · Cited by 568
Hippisley-Cox, J., & Coupland, C. (2005) · BMJ · doi:10.1136/bmj.330.7504.1366 · Cited by 561
COX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Solomon, D. H., Schneeweiss, S., Glynn, R. J., Kiyota, Y., Levin, R., Mogun, H., & Avorn, J. (2004) · Circulation · doi:10.1161/01.cir.0000127578.21885.3e · Cited by 509
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C. M., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11131-7 · Cited by 503
Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation
FitzGerald, G. A., Smith, B., Pedersen, A. K., & Brash, A. R. (1984) · New England Journal of Medicine · doi:10.1056/nejm198404263101701 · Cited by 497
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.
FitzGerald, G. A., Pedersen, A. K., & Patrono, C. (1983) · Circulation · doi:10.1161/01.cir.67.6.1174 · Cited by 466
Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout
Insel, P. (1996) · Medical Entomology and Zoology · Cited by 458
COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice
Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M., & FitzGerald, G. A. (2004) · Science · doi:10.1126/science.1103333 · Cited by 431
Reilly, I., & FitzGerald, G. (1987) · Blood · doi:10.1182/blood.v69.1.180.180 · Cited by 419
Effect of ibuprofen on cardioprotective effect of aspirin
MacDonald, T., & Wei, L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12509-3 · Cited by 419
Ott, E., Nussmeier, N. A., Duke, P. C., Feneck, R. O., Alston, R. P., Snabes, M. C., Hubbard, R. C., Hsu, P. H., Saidman, L. J., & Mangano, D. T. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00125-9 · Cited by 403
Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene.
Kujubu, D. A., & Herschman, H. R. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42398-8 · Cited by 402
Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.
Masferrer, J. L., Zweifel, B. S., Seibert, K., & Needleman, P. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114850 · Cited by 402
Jüni, P., Rutjes, A. W., & Dieppe, P. A. (2002) · BMJ · doi:10.1136/bmj.324.7349.1287 · Cited by 396
Salt–sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor
Kennedy, C. R. J., Zhang, Y., Brandon, S., Guan, Y., Coffee, K., Funk, C. D., Magnuson, M. A., Oates, J. A., Breyer, M. D., & Breyer, R. M. (1999) · Nature Medicine · doi:10.1038/5583 · Cited by 391
Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65230-3 · Cited by 379
Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With Atherosclerosis
Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J. (2000) · Circulation · doi:10.1161/01.cir.102.8.840 · Cited by 377
Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421446 · Cited by 373
van Hecken, A., Schwartz, J. I., Depré, M., de Lepeleire, I., Dallob, A., Tanaka, W., Wynants, K., Buntinx, A., Arnout, J., Wong, P. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001005 · Cited by 354
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.5.ioi50013 · Cited by 329
Leukotriene modifiers as potential therapeutics for cardiovascular disease
Funk, C. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1796 · Cited by 326
Alberto García Rodríguez, L., & Hernández-Díaz, S. (2001) · Epidemiology · doi:10.1097/00001648-200109000-00018 · Cited by 307
Zimmermann, N., Wenk, A., Kim, U., Kienzle, P., Weber, A.-A., Gams, E., Schrör, K., & Hohlfeld, T. (2003) · Circulation · doi:10.1161/01.cir.0000081770.51929.5a · Cited by 287
Watson, D. J., Rhodes, T., & Guess, H. A. (2003) · PubMed · Cited by 284
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
Capone, M. L., Sciulli, M. G., Tacconelli, S., Grana, M., Ricciotti, E., Renda, G., Di Gregorio, P., Merciaro, G., & Patrignani, P. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.045 · Cited by 279
Estimated rate of prostacyclin secretion into the circulation of normal man.
FitzGerald, G. A., Brash, A. R., Falardeau, P., & Oates, J. A. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110373 · Cited by 269
Sirois, J., Simmons, D. L., & Richards, J. S. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49951-1 · Cited by 255
Kurth, T., Glynn, R. J., Walker, A. M., Chan, K. A., Buring, J. E., Hennekens, C. H., & Gaziano, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000087593.07533.9b · Cited by 254
McAdam, B. F., Mardini, I. A., Habib, A., Burke, A., Lawson, J. A., Kapoor, S., & FitzGerald, G. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9523 · Cited by 253
Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II
Qi, Z., Hao, C., Langenbach, R. I., BREYER, R. M., Redha, R., Morrow, J. D., & Breyer, M. D. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14752 · Cited by 249
Capone, M. L., Tacconelli, S., Sciulli, M. G., Grana, M., Ricciotti, E., Minuz, P., Di Gregorio, P., Merciaro, G., Patrono, C., & Patrignani, P. (2004) · Circulation · doi:10.1161/01.cir.0000124715.27937.78 · Cited by 229
Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction
Kimmel, S. E., Berlin, J. A., Reilly, M., Jaskowiak, J., Kishel, L., Chittams, J., & Strom, B. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-3-200502010-00005 · Cited by 222
Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population
García Rodríguez, L. A., Varas-Lorenzo, C., Maguire, A., & González-Pérez, A. (2004) · Circulation · doi:10.1161/01.cir.0000132491.96623.04 · Cited by 221
Risk of cardiovascular events associated with selective COX-2 inhibitors
Mukherjee, D., Nissen, S. E., & Topol, E. J. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00545-1 · Cited by 208
Xiao, C.-Y., Hara, A., Yuhki, K.-I., Fujino, T., Ma, H., Okada, Y., Takahata, O., Yamada, T., Murata, T., Narumiya, S., et al. (2001) · Circulation · doi:10.1161/hc4301.098058 · Cited by 197
Non-Narcotic Analgesic Dose and Risk of Incident Hypertension in US Women
Forman, J. P., Stampfer, M. J., & Curhan, G. C. (2005) · Hypertension · doi:10.1161/01.hyp.0000177437.07240.70 · Cited by 196
Emerging roles for cyclooxygenase‐2 in gastrointestinal mucosal defense
Wallace, J. L., & Devchand, P. R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706201 · Cited by 168
Hennan, J. K., Huang, J., Barrett, T. D., Driscoll, E. M., Willens, D. E., Park, A. M., Crofford, L. J., & Lucchesi, B. R. (2001) · Circulation · doi:10.1161/hc3301.092790 · Cited by 163
Mediation of Inflammation by Cyclooxygenase-2
Seibert, K., Masferrer, J. L., Zhang, Y., Gregory, S. A., Olson, G. L., Hauser, S. D., Leahy, K., Perkins, W. J., & Isakson, P. C. (1995) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7276-8_5 · Cited by 162
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
Dowd, N. P., Scully, M., Adderley, S. R., Cunningham, A. J., & Fitzgerald, D. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11334 · Cited by 159
Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo
Dowd, N. P., Scully, M., Adderley, S. R., Cunningham, A. J., & Fitzgerald, D. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200111334 · Cited by 159
Inhibition of eicosanoid biosynthesis by glucocorticoids in humans.
Sebaldt, R. J., Sheller, J. R., Oates, J. A., Roberts, L. J., & FitzGerald, G. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.6974 · Cited by 155
Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation
Rosen, G. D., Birkenmeier, T. M., Raz, A., et al. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91819-6 · Cited by 152
Prostacyclin protects against elevated blood pressure and cardiac fibrosis
Francois, H., Athirakul, K., Howell, D. N., Dash, R., Mao, L., Kim, H., Rockman, H. A., FitzGerald, G. A., Koller, B. H., & Coffman, T. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.08.005 · Cited by 151
Relationship Between COX-2 Specific Inhibitors and Hypertension
Solomon, D. H., Schneeweiß, S., Levin, R., & Avorn, J. (2004) · Hypertension · doi:10.1161/01.hyp.0000136134.31846.83 · Cited by 151
Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2
Fries, S., Großer, T., Price, T. S., Lawson, J. A., Kapoor, S. C., DeMarco, S., Pletcher, M. T., Wiltshire, T., & FitzGerald, G. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.002 · Cited by 138
Selective cyclooxygenase‐2 inhibitors: similarities and differences
Brune, K., & Hinz, B. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740310004766 · Cited by 132
Parecoxib, Valdecoxib, and Cardiovascular Risk
Furberg, C. D., Psaty, B. M., & FitzGerald, G. A. (2005) · Circulation · doi:10.1161/01.cir.0000155081.76164.17 · Cited by 128
Dai, C., Stafford, R. S., & Alexander, G. C. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.2.171 · Cited by 117
Fries, J. F., Murtagh, K. N., Bennett, M. V., Zatarain, E., Lingala, B., & Bruce, B. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20440 · Cited by 117
COX-2–Derived Prostacyclin Modulates Vascular Remodeling
Rudic, R. D., Brinster, D. R., Cheng, Y., Fries, S., Song, W., Austin, S. C., Coffman, T. M., & FitzGerald, G. A. (2005) · Circulation Research · doi:10.1161/01.res.0000170888.11669.28 · Cited by 116
COX-2 is not involved in thromboxane biosynthesis by activated human platelets.
Patrignani, P., Sciulli, M. G., Manarini, S., Santini, G., Cerletti, C., & Evangelista, V. (1999) · PubMed · Cited by 115
Disease-Modifying Therapies for Osteoarthritis: Current Status
Fajardo, M., & Cesare, P. E. D. (2005) · Drugs & Aging · doi:10.2165/00002512-200522020-00005 · Cited by 107
Pidgeon, G. P., Tamošiūnienė, R., Chen, G., Leonard, I., Belton, O., Bradford, A., & Fitzgerald, D. J. (2004) · Circulation · doi:10.1161/01.cir.0000145613.01188.0b · Cited by 102
Sikes, D. H., Agrawal, N. M., Zhao, W. W., Kent, J. D., Recker, D. P., & Verburg, K. M. (2002) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200210000-00011 · Cited by 101
Hedner, T., Samulesson, O., hrborg, P. W., Wadenvik, H., Ung, K., & Ekbom, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00004 · Cited by 95
Rabausch, K., Bretschneider, E., Sarbia, M., Meyer-Kirchrath, J., Censarek, P., Pape, R., Fischer, J. W., Schrör, K., & Weber, A. (2005) · Circulation Research · doi:10.1161/01.res.0000153150.27690.f2 · Cited by 84
Cannon, C. P., Curtis, S., Bolognese, J. A., & Laine, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.024 · Cited by 78
EDLUND, A., Berglund, B., van Dorne, D., Kaijser, L., Nowak, J., Patrono, C., Sollevi, A., & Wennmalm, A. (1985) · Circulation · doi:10.1161/01.cir.71.6.1113 · Cited by 78
Rodríguez, L. A. G., & González‐Pérez, A. (2005) · BMC Medicine · doi:10.1186/1741-7015-3-17 · Cited by 76
Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition
Yu, Y., Cheng, Y., Fan, J., Chen, X., Klein–Szanto, A. J., FitzGerald, G. A., & Funk, C. D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23683 · Cited by 71
Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Tacconelli, S., Capone, M. L., & Patrignani, P. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043453108 · Cited by 70
White, W. B., Strand, V., Roberts, R., & Whelton, A. (2004) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000127360.23508.04 · Cited by 69
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, W. A., Stein, C., Daugherty, J. R., Hall, K., Arbogast, P. G., & Griffin, M. R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00991-1 · Cited by 64
Celecoxib Does Not Affect the Antiplatelet Activity of Aspirin in Healthy Volunteers
Wilner, K. D., Rushing, M., Walden, C. E., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127000204200910 · Cited by 64
Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man.
Roy, L., Knapp, H. R., Robertson, R. M., & FitzGerald, G. A. (1985) · Circulation · doi:10.1161/01.cir.71.3.434 · Cited by 64
Goulet, J. L., Pace, A. J., Key, M. L., Byrum, R. S., Nguyen, M., Tilley, S. L., Morham, S. G., Langenbach, R. J., Stock, J. L., McNeish, J. D., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1321 · Cited by 61
Hudson, M., Baron, M. G., Rahme, E., & Pilote, L. (2005) · PubMed · Cited by 48
Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*
Panara, M. R., Padovano, R., Sciulli, M. G., Santini, G., Renda, G., Rotondo, M. T., Pace, A., Patrono, C., & Patrignani, P. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90091-1 · Cited by 48
Aldington, S., Shirtcliffe, P., Weatherall, M. W., et al. (2005) · PubMed · Cited by 35
Hawkey, C. J., Farkouh, M. E., Gitton, X., Ehrsam, E., Huels, J., & Richardson, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02026.x · Cited by 32
Effect of ibuprofen on cardioprotective effect of aspirin
Etminan, M., & Samii, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13187-x · Cited by 30
Effects of Salt Loading on Blood Pressure in Mice Lacking the Prostanoid Receptor Gene
Watanabe, H., Katoh, T., Eiro, M., Iwamoto, M., Ushikubi, F., Narumiya, S., & Watanabe, T. (2004) · Circulation Journal · doi:10.1253/circj.69.124 · Cited by 29
To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk
Hermann, M., Krum, H., & Ruschitzka, F. T. (2005) · Circulation · doi:10.1161/circulationaha.105.567842 · Cited by 26
Renal arterial 20-hydroxyeicosatetraenoic acid levels: regulation by cyclooxygenase
Cheng, M. K., McGiff, J. C., & Carroll, M. A. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00239.2002 · Cited by 22
The case for an adverse interaction between aspirin and non-steroidal anti-inflammatory drugs
Curtis, J. P., & Krumholz, H. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.01.001 · Cited by 20
Meta-analysis of Cyclooxygenase-2 Inhibitors and Their Effects on Blood Pressure
Elliott, W. J. (2006) · Yearbook of Cardiology · doi:10.1016/s0145-4145(07)70029-1 · Cited by 8
Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib
Westgate, E. J., & FitzGerald, G. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020197 · Cited by 6
Biological effects of coronary surgery: role of surgical trauma and CPB
Cannata, A. (2004) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2004.05.047 · Cited by 3
Cited by
Chen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
Bindu, S., Mazumder, S., & Bandyopadhyay, U. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114147 · Cited by 1,920
Lansky, E. P., & Newman, R. A. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.09.006 · Cited by 1,290
Triggers, targets and treatments for thrombosis
Mackman, N. (2008) · Nature · doi:10.1038/nature06797 · Cited by 1,188
Metadata
- Authors
- Grosser, T.
- Venue
- Journal of Clinical Investigation
- Published
- 2005-12-08
- Volume
- 116
- Issue
- 1
- Pages
- 4-15
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2096874183
- Cited by
- 1,027
- References
- 111
- FWCI
- 46.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.